Spleen is not required for therapeutic effects of 4OH-GTS-21, a selective α7 nAChR agonist, in the sub-acute phase of ischemic stroke in rats

• Published in: Brain research 2021-01, Vol.1751, p.147196-147196, Article 147196
• Main Authors: Gaidhani, Nikhil, Kem, William R., Uteshev, Victor V.
• Format: Article
• Language: English
• Subjects: Alpha7; DMXBA; GTS-21; Ischemic stroke; Nicotinic; Spleen
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/j.brainres.2020.147196

•Ischemic brain injury was not significantly affected by splenectomy in vehicle- and 4OH-GTS-21-treated rats.•Thus, spleen is not required for therapeutic benefits of 4OH-GTS-21 after stroke.•However, spleen boosted the efficacy of 4OH-GTS-21 in adhesive sticker removal test.•Thus, 4OH-GTS-21 acts primarily centrally in the sub-acute phase of stroke.•Thus, brain availability is critical for novel therapeutic α7 ligands after stroke. Acute ischemic stroke (AIS) causes both central and peripheral inflammation, while activation of α7 nicotinic acetylcholine receptors (nAChRs) provides both central and peripheral anti-inflammatory and anti-apoptotic effects. Here, we provide evidence that 4OH-GTS-21, a selective α7 agonist, produces its therapeutic effects via primarily central sites of action because 4OH-GTS-21 was found equally effective in splenectomized and non-spenectomized rats in the sub-acute phase of ischemic stroke (≤1 week). However, the spleen may boost the therapeutic efficacy of 4OH-GTS-21 in certain behavioral tasks as our data also indicated. In our tests, AIS was modeled by transient middle cerebral artery occlusion (tMCAO). Splenectomy was done 2 weeks before tMCAO. We determined that: 1) Daily 4OH-GTS-21 treatments for 7 days after tMCAO significantly reduced neurological deficits and brain injury in both splenectomized and non-spelenectomized rats demonstrating that the spleen is not required for therapeutic benefits of 4OH-GTS-21; 2) The effects of 4OH-GTS-21 in the adhesive sticker removal test were significantly weaker in splenectomized animals suggesting that the spleen boosts the efficacy of 4OH-GTS-21 in the first week after tMCAO; and 3) Ischemic brain injury was not significantly affected by splenectomy in both vehicle-treated and 4OH-GTS-21-treated animals. These data support the hypothesis that the therapeutic efficacy of sub-chronic (≤1 week) 4OH-GTS-21 primarily originates from central sites of action. These results validate brain availability as a critical factor for developing novel α7 ligands for AIS.